Aurobindo Pharma Targets U.S. Oncology Segment with Pomalidomide Launch

Aurobindo Pharma announced that its wholly‑owned subsidiary, Eugia Pharma Specialities, has launched Pomalidomide Capsules in strengths of 1 mg, 2 mg, 3 mg and 4 mg in the U.S. market. The product is the generic version of Pomalyst Capsules marketed by BMS Pharmaceuticals Corp.

Eugia Pharma Specialities was among the First‑to‑File applicants for this formulation under the ANDA route. Manufacturing for the product will take place at Eugia Unit‑I.

Launch Details and Regulatory Background

The launch marks Eugia Pharma Specialities’ entry into an important product category tied to oncology and immunomodulatory therapies. Being among the First‑to‑File applicants positions the product for early commercial presence within the generic segment.

The manufacturing location at Eugia Unit‑I ensures production continuity for all four capsule strengths. The approval follows the standard abbreviated new drug application process used for generic equivalents in the U.S. market.

Product Profile and Therapeutic Use

Pomalidomide is a third‑generation immunomodulatory drug used in the management of relapsed or refractory multiple myeloma. It is prescribed in combination with dexamethasone and occasionally bortezomib, depending on the treatment protocol.

The drug is also used for AIDS‑related Kaposi sarcoma, supporting treatment outcomes in complex clinical cases. The broad therapeutic relevance of Pomalidomide contributes to its significant market demand across oncology centres.

Market Size and U.S. Commercial Potential

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules represent an estimated market size of approximately US$ 3.3 billion in the U.S. market. The sizeable market value indicates strong ongoing demand for both originator and generic formulations.

The entry of a First‑to‑File applicant strengthens competition within the segment and expands patient access to lower‑cost therapeutic alternatives. The launch positions Eugia Pharma Specialities to participate in one of the larger oncology‑linked generic categories in the U.S.

Company Background and Recent Financial Performance

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic medicines and associated services. Its operations span multiple therapeutic areas, supported by domestic and international regulatory approvals.

The company reported consolidated net profit of ₹910.29 crore in Q3 FY26, marking a 7.6% increase over Q3 FY25. Net sales rose 9% year‑on‑year to ₹8,604.51 crore during the same quarter, reflecting continued operational growth.

Conclusion

Aurobindo Pharma’s launch of generic Pomalidomide Capsules in the U.S. expands the company’s presence in a high‑value oncology segment. The product’s First‑to‑File status and manufacturing at Eugia Unit‑I support its entry into a large and competitive therapeutic market.

The launch adds to the company’s portfolio of advanced generics and strengthens its international footprint. Recent financial performance provides further context to the company’s ongoing expansion efforts.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.